Table 3. Main results and publication bias for the meta-analysis between BUB1B and clinicopathological features, overall survival (OS), and progression-free survival (PFS).
| Clinicopathological features/OS/PFS | Number of included datasets | SMD/HR(95%CI) | Z, p value | Heterogeneity test (I2, p value) | Publication bias (Begg’s test) (Z, p value) | Pooling model |
|---|---|---|---|---|---|---|
| Age (<=65/>65) | 14 | 0.109 (0.028, 0.190) | 2.63, 0.009 | 0%, 0.510 | 0.44, 0.661 | Fixed |
| Sex (Male/Female) | 15 | 0.198 (0.133, 0.262) | 6.01, <0.001 | 43.3%, 0.058 | 0.69, 0.488 | Fixed |
| Smoking status (Yes/No) | 10 | 0.428 (0.310, 0.546) | 7.11, <0.001 | 31.5%, 0.157 | 0.36, 0.721 | Fixed |
| T stage (T2/T1) | 6 | 0.428 (0.310, 0.545) | 7.14, <0.001 | 37.2%, 0.158 | 1.88, 0.060 | Fixed |
| T stage (T3-T4/T1-T2) | 4 | 0.295 (0.124, 0.466) | 3.38, 0.001 | 43.6%, 0.150 | 0.34, 0.734 | Fixed |
| N stage (N1/N0) | 6 | 0.199 (0.057, 0.341) | 2.74, 0.006 | 26.8%, 0.233 | 1.13, 0.260 | Fixed |
| N stage (N2-N3/N0-N1) | 4 | 0.183 (0.011, 0.355) | 2.09, 0.037 | 0%, 0.459 | 0.34, 0.734 | Fixed |
| M stage (M1/M0) | 5 | 0.293 (0.036, 0.550) | 2.24, 0.025 | 7.4%, 0.365 | -0.24, 1.000 | Fixed |
| AJCC stage (II/I) | 12 | 0.287 (0.178, 0.396) | 5.15, <0.001 | 0%, 0.776 | 0.89, 0.373 | Fixed |
| AJCC stage (III-IV/I-II) | 9 | 0.126 (0.008,0.243) | 2.10, 0.036 | 0%, 0.989 | 1.77, 0.067 | Fixed |
| OS | 15 | 1.263 (1.187, 1.340) | 32.41, <0.001 | 39.4%, 0.058 | 0.59, 0.553 | Fixed |
| PFS | 11 | 1.243 (1.150, 1.336) | 26.17, <0.001 | 32.2%, 0.142 | 0.31, 0.755 | Fixed |